Literature DB >> 2793921

The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries.

H Z Zokufa1, L D Solem, K A Rodvold, K B Crossley, J H Fischer, J C Rotschafer.   

Abstract

Ten patients with burn injuries (mean total body surface area burn = 29% +/- 16) were studied at various points in the course of their burn therapy. Alpha 1-Acid glycoprotein, albumin, and vancomycin concentrations were determined with either a trough or peak vancomycin quantitative determination. Alpha 1-Acid glycoprotein concentrations ranged from 125 to 333 mg/dl and albumin concentrations ranged from 1.7 to 4.2 gm/dl. Vancomycin protein binding, as determined by ultrafiltration, averaged 29% +/- 6%. There was a strong (r = 0.92) relationship between percent protein-bound vancomycin and albumin. There was a poor statistical relationship between percent protein-bound vancomycin and alpha 1-acid glycoprotein (r = 0.28). Alpha 1-Acid glycoprotein appeared to have virtually no effect on the protein-binding characteristics of vancomycin over the range of concentrations studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2793921     DOI: 10.1097/00004630-198909000-00010

Source DB:  PubMed          Journal:  J Burn Care Rehabil        ISSN: 0273-8481


  9 in total

1.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

3.  Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.

Authors:  Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich
Journal:  Can J Hosp Pharm       Date:  2010-05

4.  Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.

Authors:  Jack Brown; Kristen Brown; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.

Authors:  Didi Bury; Rob Ter Heine; Ewoudt M W van de Garde; Marten R Nijziel; Rene J Grouls; Maarten J Deenen
Journal:  Eur J Clin Pharmacol       Date:  2019-03-15       Impact factor: 2.953

Review 7.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Factors impacting unbound vancomycin concentrations in neonates and young infants.

Authors:  Anne Smits; Steven Pauwels; Matthijs Oyaert; Nele Peersman; Isabel Spriet; Veroniek Saegeman; Karel Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-16       Impact factor: 3.267

Review 9.  Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States.

Authors:  Marie N Celestin; Florin M Musteata
Journal:  J Pharm Sci       Date:  2021-06-02       Impact factor: 3.784

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.